Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Top 5 Coins for the Maximum Passive Income from Staking by 2024

February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024

Staking is one of the ways that is now being used as a secure and profitable way to earn money without doing anything…
Trading Stocks With AI: A Modern Approach

January 21, 2025 Trading Stocks With AI: A Modern Approach

The stock market can feel overwhelming, especially with its constant ups and downs. Trading stocks with AI is revolutionizing how investors analyze trends,…
Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025

The launch of spot Bitcoin (CRYPTO: BTC) exchange-traded funds (ETFs) in January 2025 marked a turning point in the cryptocurrency market. These ETFs…
Advanced Charting Tools For Traders

January 1, 2025 Advanced Charting Tools For Traders

Ever tried deciphering market trends with the intensity of a detective peering over cryptic clues? Enter the realm of Advanced Charting, where complex…
Why Is Trading Important?

December 21, 2024 Why Is Trading Important?

Trade isn’t just figures on a spreadsheet; it’s the pulse of our global community. In 2018, the United States faced a staggering $621…

Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: February 16, 2025 (09:58)

Sector: Healthcare

The share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now

Latest session on the 14th of February for
Teva Pharmaceutical Industries Lim. (TEVA) is negative
Trading Volume: 12474918
Open: 16.58 /  High: 16.63 /  Low: 16.08
Current value: $16.25
What analysts predict: $24.5
52-week High/Low: $22.8 / $12.51
50-Day Moving Average: $19.62 — resistance level today
200-Day Moving Average: $17.75 — resistance level today

News Impact Analyzer

Full report
This Week
Bullish Impact: 5 News: 2 (1/1/0)
Previous Week
Bearish Impact: 5 News: 3
Two Weeks Ago
Bearish Impact: 1.67 News: 4 (1/1/2)
Three Weeks Ago
Bearish Impact: 5 News: 2

Analysts predictions

Full report
This Week
Neutral Opinions: 1
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Neutral Opinions: 1
Three Weeks Ago
Neutral Opinions: Na

Analyzing the Most Important TEVA news

Axsome and Teva Reach Settlement Over Antidepressant Patent Clash

Feb 10, 2025
Trend: Neutral
Influence: 5
The settlement removes short-term legal uncertainty for Teva but doesn't indicate significant upside or downside for its stock. While the issue is resolved, the market impact is likely limited since no critical financial details or market-changing developments were disclosed. Investors will likely remain cautious until more clarity emerges on Teva's generics strategy regarding Auvelity.

Teva Completes Phase 3 Trial for Long-Acting Schizophrenia Drug

Feb 10, 2025
Trend: Bullish
Influence: 8
The successful completion of Teva's Phase 3 trial for an innovative schizophrenia drug signals a potential new revenue stream, strengthening its pipeline. This milestone increases investor confidence in the company's R&D capabilities and could positively impact the stock price. The market likely views the progress toward commercialization as a significant growth opportunity.

Teva Pharmaceuticals Announces Potential for Multi-Security Capital Raise

Feb 07, 2025
Trend: Neutral
Influence: 5
The mixed shelf offering indicates Teva's potential need for raising capital, which could dilute existing shares if ADSs are issued. However, the flexibility to include debt or other securities may limit the downside. The long-term impact depends on the use of the capital and market conditions, making the immediate effect on stock price uncertain.

Historical and forecast chart of Teva stock

The chart below shows the historical price of Teva stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.

Long-term forecasts by years.

Teva Pharmaceutical Industries Lim. (TEVA) Analysts predictions review

Teva Pharmaceuticals faces near-term challenges from revised guidance, generic drug pricing pressures, legal liabilities, and macroeconomic risks like inflation and supply chain disruptions. However, its strategic shift towards high-margin specialty drugs, pipeline strength in biosimilars and innovative products like Duvakitug, and cost optimization initiatives signal potential for long-term recovery. Execution risks, competition, and regulatory dependencies remain key concerns. Investors should adopt a cautious stance given the balance of opportunities and risks.

Teva Pharmaceutical: 2025 Guidance Unveils Short-Term Risks, Long-Term Potential

Trend: Neutral
Jan 30, 2025

Teva Pharmaceutical's revised 2025 guidance has been a key trigger for the stock's recent decline. A downward adjustment in revenue and profitability expectations signals near-term challenges in sustaining growth, reflecting ongoing pressure from generic drug pricing and legislative risks. These factors have notably tempered investor sentiment, amplifying volatility in the stock.

Potential Catalysts for Value Recovery Despite Challenges

Despite the lowered guidance, the company's focus on cost optimization and its ongoing pivot towards higher-margin specialty drugs could provide a medium to long-term growth runway. This strategic shift aligns with an evolving market environment and could help Teva mitigate margin compression in the commoditized generics segment.

Additionally, the pipeline of biosimilars and novel therapeutics remains an underappreciated asset in Teva's portfolio. Successful commercialization of these products could unlock significant value, compensating for revenue pressure in traditional segments and sparking a stock recovery over time.


Analyst: Brendan O'Boyle
( Followers: 1703
Articles: 118 )

Evaluating TEVA Pharmaceuticals: A Strategic Outlook Amid Immunology Market Growth

Trend: Neutral
Jan 19, 2025

TEVA Pharmaceuticals stands at a critical juncture within the immunology sector, benefiting from its diversified portfolio and a solid pipeline of drug development. Its position as a major player in the generic drugs market continues to provide the company with a cash flow safety net, enabling long-term investments in innovative treatments. However, intense competition in both generics and specialty drugs remains a notable pressure point for margins.

Growth Drivers and Challenges for TEVA

TEVA's recent focus on expanding its immunology offerings reflects a strategic pivot towards high-margin specialty drugs to counteract ongoing pricing struggles in the generics segment. This shift is likely to bolster revenue growth in the medium to long term if clinical trials and regulatory approvals proceed as planned. Additionally, the company's cost optimization measures, including facility consolidations and operating expense reductions, signal improved efficiency and profitability potential, which investors will closely monitor for tangible results in quarterly earnings.

On the downside, ongoing legal liabilities from opioid-related settlements present a recurring headwind for TEVA, adding uncertainty to future cash flow allocations. Moreover, foreign exchange volatility, given its significant international footprint, could further pressure earnings in the near term.

The author underscores that while TEVA exhibits significant long-term potential tied to its R&D efforts and market pivots, near-term risks warrant a cautious approach. Investors seeking exposure should weigh these opportunities against the risks of delayed regulatory approvals and macroeconomic challenges.


Analyst: ALLKA Research
( Followers: 1397
Articles: 49 )

Teva Pharmaceuticals: Evaluating Duvakitug's Role in Long-Term Growth

Trend: Neutral
Dec 27, 2024

Teva Pharmaceuticals' strategic focus on Duvakitug, a novel pharmaceutical product, highlights the company's efforts to revitalize its growth trajectory amidst a challenging competitive landscape. The drug is positioned as a potential breakthrough in its therapeutic category, potentially driving meaningful revenue growth if it gains strong market adoption and regulatory support. The author emphasizes the significance of this pipeline asset, underscoring its role in boosting confidence in Teva's innovation capabilities and long-term value.

Macroeconomic Environment and Operational Challenges

Broader macroeconomic conditions, including inflationary pressures and global supply chain disruptions, remain critical challenges for Teva. These factors could compress margins and slow operational recovery, especially as the company continues its debt-reduction efforts. The author also notes increased competition in the generics market, which may dampen price growth and offset revenue gains from innovative products like Duvakitug.

Cost management initiatives and restructuring measures are additional levers influencing Teva’s financial health. While these actions may enhance operational efficiency, they are not without execution risks that could delay the realization of cost savings. Furthermore, litigation risks stemming from opioid-related settlements could weigh on investor sentiment and potentially impact near-term stock performance.


Analyst: ALLKA Research
( Followers: 1314
Articles: 48 )
Dec 04, 2024
Teva: Stable Progress Amid Shrinking Valuation Upside
Trend: Neutral

Teva's operational fundamentals have shown significant improvement, particularly through its consistent focus on debt reduction and cost efficiencies. These actions signal strong financial discipline that enhances long-term sustainability, though they may have minimal immediate impact on driving the stock price higher in the near term.

Valuation and Growth Outlook

The author's analysis suggests that Teva's current valuation aligns with its improving fundamentals, reducing the likelihood of it being an undervalued opportunity. This equilibrium limits substantial upside potential unless new growth catalysts emerge or sector-wide sentiment improves.

Additionally, short-term headwinds, such as ongoing legal challenges and competition in generic drugs, remain key risks restraining price momentum. These elements weigh on investor confidence and have the potential to maintain pressure on the stock's near-term performance.

Analyst: Eugenio Catone
( Followers: 3307
Articles: 346 )
Oct 23, 2024
Teva Pharmaceuticals: A Strategic Buy Amid Debt Reduction and Growth Catalysts
Trend: Bullish

Teva Pharmaceuticals is capitalizing on its position as a leading generic drug manufacturer, which continues to drive stable revenue, particularly amidst rising demand for cost-effective healthcare solutions. The company’s dominance in generics insulates it against major competitive pressures, enhancing its allure as a long-term investment.

Leveraging Financial Discipline and Growth Prospects

Teva’s proactive debt reduction strategy has significantly strengthened its balance sheet, lowering financial risk and enhancing its capacity to reinvest in core operations. The removal of onerous financial obligations improves investor sentiment and positions the company for better forward-looking profitability.

Growth indicators, including new product launches and strategic market expansions, highlight management’s focus on innovation and operational efficiency. These developments provide tailwinds for revenue acceleration and improved market positioning in the near to medium term.

Finally, macroeconomic factors such as inflationary pressures and global healthcare trends are likely to favor Teva’s cost-effective drug offerings. As governments and insurers push for reduced healthcare expenditures, Teva is well-placed to benefit from elevated demand in key markets.

Analyst: Albert Anthony
( Followers: 1155
Articles: 278 )

Comprehensive Analysis of Teva (TEVA) Stock Market Performance


Our multifaceted analysis of Teva 's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Teva stock?
  • When should I record a loss on Teva stock?
  • What are analysts' forecasts for Teva stock?
  • What is the future of Teva stock?

We forecast Teva stock performance using neural networks based on historical data on Teva stocks.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.

Teva Pharmaceutical Industries Lim. (TEVA) News influencing stock rates

As of now, Panda has combed through 11 news items directly related to TEVA from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 5 display bearish tendencies, and 4 events are neutral.

The strength of the bearish trend is dominating bullish sentiments by 2.06 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.

The news analyzed fell within the period from Jan 17, 2025, to Feb 10, 2025.

βeta
Feb 05, 2025

Teva Pharmaceutical Rebounds After 20% Plunge in Six Sessions

Trend: Neutral
Influence: 4
The 0.88% recovery after significant losses signals a temporary halt in bearish momentum rather than a strong reversal. With an 18.5% monthly decline, the context remains cautious. The post has moderate influence due to its reflection of short-term stabilization but lacks substantial news or catalysts to suggest a strong directional change in TEVA's stock.
Feb 03, 2025

Tariff Concerns Loom Over Pharma Distributors and Generic Drugmakers

Trend: Bearish
Influence: 7
Tariffs on Canada, China, and Mexico could disrupt the supply chain for generic drugmakers like TEVA, leading to increased costs and lower margins. This creates bearish sentiment due to potential financial strain. The mid-level influence reflects significant risks to operations and profitability, though broader geopolitical dynamics may moderate the final impact.
Jan 29, 2025

Stock Market Spotlight: Key Movers on Earnings Day

Trend: Neutral
Influence: 2
The provided post does not mention TEVA directly, thus its influence on TEVA's stock is minimal. Focused mainly on tech companies and the Federal Reserve, the content could only indirectly affect TEVA's market environment. The neutral trend and low influence score are due to the lack of direct relevance to TEVA's current business activities or performance.
Jan 29, 2025

Teva Surpasses Q4 Expectations: Sets Bold 2025 Outlook

Trend: Bullish
Influence: 8
Teva's better-than-expected Q4 earnings and revenue reflect strong operational performance, suggesting robust future growth potential. The inclusion of a 2025 outlook indicates confidence in sustained growth, likely boosting investor sentiment. This positive news should contribute to upward momentum in the stock price, making it a bullish trend with significant influence on market perception and potential price change.
Jan 29, 2025

Teva Stumbles as 2025 Earnings Fall Short

Trend: Bearish
Influence: 7
Teva's stock drop indicates a bearish trend as its 2025 earnings outlook failed to meet expectations, despite strong Q4 2024 results. Market disappointment in future earnings potential influences investor sentiment negatively. The substantial 5% premarket decline suggests significant confidence loss, likely maintaining downward pressure on the stock in the short-term.
Jan 28, 2025

Teva Faces Uphill Struggle with Q4 Earnings Decline

Trend: Bearish
Influence: 7
Teva's Q4 earnings preview shows a significant decline in both EPS and revenue year-over-year, indicating operational challenges. The 30% drop in EPS and 7.6% revenue fall signal potential market pressure, likely affecting investor confidence negatively. The bearish trend reflects these concerns with a substantial influence level of 7, pointing to potential downward pressure on TEVA's stock price.
Jan 22, 2025

FDA Flags Severe Allergy Risk in Teva's Copaxone

Trend: Bearish
Influence: 6
The FDA's addition of a boxed warning for Copaxone due to anaphylaxis risk introduces a negative sentiment for TEVA. Although the risk is rare, investor concern over potential litigation and reduced sales could pressure the stock. This represents moderate influence, as drugs with warnings may experience diminished market confidence, affecting the company's financial outlook negatively.
Jan 17, 2025

Teva Challenges Medicare Drug Pricing in Court

Trend: Bearish
Influence: 7
Teva's lawsuit against the CMS signals potential legal battles and regulatory hurdles, which could lead to increased uncertainty and financial strain. This development might negatively impact investor sentiment, suggesting a potential dip in stock price. The level of influence is significant due to possible repercussions on future revenues and market positioning in healthcare pricing regulations.
Jan 13, 2025

Teva Expands European Footprint with Eylea Biosimilar Deal

Trend: Bullish
Influence: 7
The strategic partnership with Klinge and Formycon for Eylea's biosimilar commercialization in Europe and Israel is a significant step for Teva. This move aligns with growing demand for cost-effective biosimilars, potentially expanding market access and bolstering revenue. The collaboration reinforces Teva's presence in key geographic regions, contributing to a positive outlook on its stock in the near future.
Jan 10, 2025

Teva Teams Up with Samsung Bioepis for U.S. Biosimilar Launch of EPYSQLI

Trend: Bullish
Influence: 7
The partnership with Samsung Bioepis to commercialize EPYSQLI in the U.S. highlights Teva's strategic focus on expanding its biosimilar portfolio, which is a growth area in the pharmaceutical industry. This move is likely to enhance revenue streams and strengthen its market position, positively impacting TEVA's stock price in the short to medium term.

Trending Themes in the Healthcare Sector

Teva daily forecast for a month

Date Target Pes. Opt. Vol., %
Feb 18 17.58 16.97 17.81 4.97
Feb 19 17.39 16.64 18.04 8.40
Feb 20 17.78 17.56 18.41 4.86
Feb 21 16.82 16.23 17.62 8.58
Feb 22 17.75 17.00 18.40 8.27
Feb 23 17.66 17.03 18.10 6.28
Feb 24 17.75 17.37 18.20 4.78
Feb 25 17.69 17.09 18.49 8.13
Feb 26 17.91 17.40 18.59 6.86
Feb 27 17.47 17.24 18.01 4.44
Feb 28 16.46 16.02 16.89 5.43
Mar 01 17.09 16.80 17.90 6.53
Mar 02 17.98 17.17 18.27 6.41
Mar 03 19.06 18.46 19.63 6.32
Mar 04 18.74 18.02 19.27 6.93
Mar 05 18.30 17.81 18.91 6.23
Mar 06 19.19 18.71 19.73 5.48
Mar 07 19.43 19.12 19.76 3.35
Mar 08 18.92 18.47 19.51 5.59
Mar 09 18.87 18.39 19.40 5.54
Mar 10 18.89 18.58 19.25 3.60
Mar 11 18.58 18.20 19.09 4.90
Mar 12 19.38 18.68 19.81 6.04
Mar 13 19.67 19.16 20.18 5.30
Mar 14 20.19 19.55 20.65 5.64
Mar 15 21.22 20.34 22.15 8.89
Mar 16 20.52 19.55 20.93 7.05
Mar 17 19.31 18.57 19.95 7.42
Mar 18 19.27 19.04 19.61 3.04
Mar 19 19.51 19.22 20.22 5.24

Teva Daily Price Targets


Teva Stock Forecast 02-18-2025.

Forecast target price for 02-18-2025: $17.58.
Positive dynamics for Teva shares will prevail with possible volatility of 4.737%.
Pessimistic target level: 16.97
Optimistic target level: 17.81

Teva Stock Forecast 02-19-2025.

Forecast target price for 02-19-2025: $17.39.
Negative dynamics for Teva shares will prevail with possible volatility of 7.751%.
Pessimistic target level: 16.64
Optimistic target level: 18.04

Teva Stock Forecast 02-20-2025.

Forecast target price for 02-20-2025: $17.78.
Positive dynamics for Teva shares will prevail with possible volatility of 4.633%.
Pessimistic target level: 17.56
Optimistic target level: 18.41

Teva Stock Forecast 02-21-2025.

Forecast target price for 02-21-2025: $16.82.
Negative dynamics for Teva shares will prevail with possible volatility of 7.901%.
Pessimistic target level: 16.23
Optimistic target level: 17.62

Teva Stock Forecast 02-22-2025.

Forecast target price for 02-22-2025: $17.75.
Positive dynamics for Teva shares will prevail with possible volatility of 7.641%.
Pessimistic target level: 17.00
Optimistic target level: 18.40

Teva Stock Forecast 02-23-2025.

Forecast target price for 02-23-2025: $17.66.
Negative dynamics for Teva shares will prevail with possible volatility of 5.911%.
Pessimistic target level: 17.03
Optimistic target level: 18.10

TEVA (TEVA) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Mar. 15.86 15.00 16.39 8.51
Apr. 16.14 15.29 18.05 15.31
May. 15.78 14.72 17.34 15.14
Jun. 13.30 12.62 13.77 8.35
Jul. 11.24 10.70 12.46 14.14
Aug. 11.22 10.25 12.23 16.15
Sep. 10.82 9.87 12.12 18.57
Oct. 11.40 10.28 12.02 14.42
Nov. 11.85 11.42 12.59 9.34
Dec. 10.77 9.77 11.74 16.74

Teva forecast for this year


Teva Stock Prediction for Mar 2025

An downtrend is forecast for this month with an optimal target price of $15.8584. Pessimistic: $15.00. Optimistic: $16.39


Teva Stock Prediction for Apr 2025

An uptrend is forecast for this month with an optimal target price of $16.1375. Pessimistic: $15.29. Optimistic: $18.05


Teva Stock Prediction for May 2025

An downtrend is forecast for this month with an optimal target price of $15.776. Pessimistic: $14.72. Optimistic: $17.34


Teva Stock Prediction for Jun 2025

An downtrend is forecast for this month with an optimal target price of $13.3023. Pessimistic: $12.62. Optimistic: $13.77


Teva Stock Prediction for Jul 2025

An downtrend is forecast for this month with an optimal target price of $11.2378. Pessimistic: $10.70. Optimistic: $12.46


Teva Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $11.2198. Pessimistic: $10.25. Optimistic: $12.23


Teva Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $10.8249. Pessimistic: $9.87. Optimistic: $12.12


Teva Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $11.3964. Pessimistic: $10.28. Optimistic: $12.02


Teva Stock Prediction for Nov 2025

An uptrend is forecast for this month with an optimal target price of $11.8523. Pessimistic: $11.42. Optimistic: $12.59


Teva Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $10.7714. Pessimistic: $9.77. Optimistic: $11.74



Teva (TEVA) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 10.55 9.77 10.92 10.51
Feb 10.02 8.87 11.31 21.56
Mar 9.75 9.27 10.42 11.08
Apr 11.28 10.11 12.15 16.79
May 11.61 10.57 12.63 16.32
Jun 11.55 11.11 12.71 12.65
Jul 12.31 11.42 13.80 17.26
Aug 13.15 11.77 13.64 13.73
Sep 13.43 12.46 14.18 12.12
Oct 13.45 12.95 14.33 9.61
Nov 12.14 11.61 12.93 10.21
Dec 11.65 10.96 12.15 9.82

Teva (TEVA) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 11.52 10.27 12.87 20.20
Feb 10.69 9.84 12.04 18.32
Mar 12.26 11.42 13.34 14.41
Apr 13.05 11.42 13.80 17.25
May 12.95 11.29 13.46 16.15
Jun 13.69 13.10 14.41 9.12
Jul 11.87 10.54 13.28 20.60
Aug 12.23 11.14 13.39 16.81
Sep 10.63 10.29 11.94 13.82
Oct 10.17 9.45 11.02 14.18
Nov 10.80 10.29 11.98 14.14
Dec 10.56 9.60 10.92 12.07

Teva information and performance

Teva Address

5 BAZEL ST, P O B 3190, PETACH TIKVA, IL

Market Capitalization: 18 874 661 000 $

Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.

EBITDA: 4 786 000 000 $

EBITDA of Teva is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.002

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.43

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.4
Quarterly Revenue Growth YOY: 0.125
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 6.39

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.034

Enterprise Value (EV) /Revenue

EV To EBITDA: 43.31

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 1133840000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Teva (TEVA) stock dividend

Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Teva Stock)

Should I Buy Teva Shares in 2025 year?

The maximum forecasted share price for next year is $13.45, Это на 2.80$ меньше чем текущая цена акций. Инвестируя сегодня в акции Teva на срок 1 год вы получите убыток в размере 17.24%. With an investment horizon of up to two years, the target share price is 13.69$. Убыток: 15.75% (-2.56$ на каждую акцию).

Does Teva pay dividends?

No, it does not

Which economic sector do Teva 's shares belong to?

Teva 's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Teva 's shares?

You can view all the stocks that are part of the same sector as Teva 's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.